Sponsor: SWOG
Sponsor Study ID: S2107
Study Title: Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
CTO #: 103744
NCT Number: NCT05308446
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Colon
Study Objectives: To compare progression-free survival (PFS) per RECIST 1.1 in patients with microsatellite stable (MSS), BRAFV600E metastatic and/or unresectable colorectal cancer (CRC) randomized to treatment with nivolumab + encorafenib + cetuximab compared to encorafenib + cetuximab.